While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...

Public health became an unlikely hot topic in the waning days of the US election, with Trump saying he would let Robert F ...

Dr Nisa Aslam said that coughs and colds are taking longer to dissipate and that patients are experiencing more severe ...